<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36665">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01708421</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00037891</org_study_id>
    <nct_id>NCT01708421</nct_id>
  </id_info>
  <brief_title>Symptom Clusters in Children With Leukemia</brief_title>
  <official_title>Phenotypic and Genotypic Associations With Symptom Clusters During Childhood Leukemia Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the phenotypic and genotypic characteristics and
      their associations with symptom clusters experienced during treatment for childhood
      leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A repeated measures research design will evaluate phenotypic and genotypic treatment-related
      symptom associations experienced by children and adolescents 3-17 years of age with a
      diagnosis of leukemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Childhood Leukemia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A baseline CSF sample will be obtained prior to intrathecal chemotherapy. CSF biomarkers
      will be obtained at the initiation of post-induction, 4 and 6 months into post-induction
      therapy, and at the start of maintenance therapy.A saliva sample will be obtained for
      genotypic analysis at one of the four data collection times.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children between 3-18 years of age undergoing treatment for leukemia.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phenotypic and genotypic treatment-related symptom associations will be evaluated in
             children and adolescents 3-18 years of age with a diagnosis of leukemia.

        Exclusion Criteria:

          -  Children without a definite diagnosis of leukemia will be excluded.

          -  Children must be able to understand and answer the questions on the questionnaires.

          -  Children with have a cognitive impairment (e.g. Down syndrome) will not be able to
             complete the questionnaires and will not be eligible for the study.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marilyn Hockenberyy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University School of Nursing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marilyn Hockenberry, PhD</last_name>
    <phone>919-684-9330</phone>
    <email>marilyn.hockenberry@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marilyn Hockenberry, PhD</last_name>
      <phone>919-684-9330</phone>
    </contact>
    <investigator>
      <last_name>Sharron Docherty, PhD,CPNP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 31, 2014</lastchanged_date>
  <firstreceived_date>October 15, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
